Marketing approval authorisation

Stamp of approval
#CHMP #EMA #European Medicines Agency #European Union #Marketing approval authorisation

EU’s CHMP supports 14 new medicines, but rejects lecanemab

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More

#News #Regulatory #Trending News

Scotland
#Lymphoma #Marketing approval authorisation #NHS Scotland #Scottish Medicines Consortium (SMC) #Ulcerative colitis (UC) #Weight loss

Scottish Medicines Consortium advises on six new drugs

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHS Scotland, has published advice on six medicines. 1. Tirzepatide (Mounjaro) was accepted for weight management in adults and is to be used alongside diet and exercise to help people lose weight. It was also given… Read More

#News #Regulatory

#ABPI #Marketing approval authorisation #MHRA #Regulatory #UK

New UK authorisation policy draws on international drug approvals

The UK Medicines and Healthcare products Regulatory Agency’s (MHRA) new International Recognition procedure (IRP) will allow it to draw on the expertise of regulators in other countries when authorising medicines. The MHRA will retain ultimate authority to accept or reject applications submitted under the IRP, but it is hoped that… Read More

#News #Regulatory

Bladder cancer
#Bladder cancer #EMA #Janssen #Marketing approval authorisation #Regulatory #Urothelial carcinoma

Janssen submits EMA filing for bladder cancer treatment 

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3)… Read More

#Cancer Research #News

Stamp of approval
#CHMP #EMA #Marketing approval authorisation #Regulatory

The CHMP recommends 14 new medicines for approval

The EU’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorisation for 14 new medicines in its July meeting. The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant), a vaccine to protect small infants and older people against lower respiratory tract… Read More

#News #Regulatory

FDA
#Drug approvals #FDA #Marketing approval authorisation #Regulatory #United States

The regulatory round-up: Five important FDA approvals

The US Food and Drug Administration (FDA) has granted marketing authorisations to several new therapeutics over the last month that will have a significant impact on areas of unmet need and the evolution of future treatments. Elevidys, Sarepta Therapeutics Elevidys became the first gene therapy for Duchenne muscular dystrophy (DMD)… Read More

#News #Regulatory

Lottery
#EFPIA #Europe #Marketing approval authorisation #Regulatory

EFPIA report highlights Europe’s medicines lottery

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a series of reports about the availability of new medicines throughout Europe. EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37 countries in the EU… Read More

#News #Regulatory #Trending News

FDA
#Drug approvals #FDA #Marketing approval authorisation #Regulatory #United States

The regulatory round-up: Eight key FDA decisions

The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. Here’s a summary. Orserdu (elacestrant), Stemline Therapeutics The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer was approved in… Read More

#Exclusive Content #Regulatory

Scotland
#Gilead Sciences #hepatitis #Immunology / Virology & Vaccines #Marketing approval authorisation #Scottish Medicines Consortium (SMC)

Scottish regulator approves first chronic hepatitis delta virus drug

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. The drug has been accepted for the treatment of chronic HDV infection in adult patients with evidence of… Read More

#News #Regulatory

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

#CHMP #EMA #Ipsen #Marketing approval authorisation #Phase III trial #Regulatory

CHMP rejects rare bone disease treatment in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP).   The company says it will be requesting a re-examination of the CHMP opinion, based on scientific… Read More

#News #Regulatory

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News

#AstraZeneca #Covid-19 #Marketing approval authorisation #MHRA

Covid-19 approval milestone for those who can’t be vaccinated 

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first antibody combination for pre-exposure prophylaxis (PrEP) against Covid-19 licensed in Great Britain.   The use of this medicine is for adults who are not currently… Read More

#News #Trending News

Pills
#Approvals #Covid-19 #Marketing approval authorisation

NICE expands guidance for AstraZeneca’s hyperkalaemia drug

The National Institute for Health and Care Excellence (NICE) has updated Technology Appraisal Guidance (TAG) TA599 for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) in the treatment of adult patients with hyperkalaemia in England, Wales, and Northern Ireland.   Context   This guidance update follows the removal of the previous commercial arrangement, meaning… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Marketing approval authorisation

Pfizer / BioNTech vaccine approved and available for use in the UK next week

The Pfizer/BioNTech COVID-19 vaccine has been authorised for emergency use by the Medicines and Healthcare Products Regulatory Authority (MHRA). Pfizer and BioNTech recently announced final efficacy analysis in their Phase III study for their mRNA-based COVID-19 vaccine candidate BNT162b2, which showed an efficacy rate of 95% in participants without prior… Read More

#Covid-19 #News #Trending News

#Marketing approval authorisation #Pharmacovigilance #Regulatory

Pharmacovigilance audits: implications of poor pass rates for drug developers

Vanessa Fachada Oliveira, Pharmacovigilance Manager & EU QPPV at Arriello, discusses 10 common issues identified in risk-based audits, and pinpoints implications for drug developers as well as marketing authorisation holders (MAHs). In EU markets, pharmacovigilance (PV) provisions are closely monitored to ensure that patients can have maximum confidence in the safety… Read More

#Exclusive Content #Regulatory